Experiment Overview
Hypothesis being tested: Exercise-BDNF-Mitochondrial Resilience Hypothesis
Primary Objective: Determine whether physical exercise-induced BDNF elevation correlates with improved mitochondrial quality control markers and reduced neuroinflammation in Parkinson's Disease patients.
Study Design: Prospective cohort study with 12-month follow-up
Study Population
Inclusion Criteria
- Age 45-75 years
- Diagnosis of idiopathic Parkinson's Disease (UK Brain Bank criteria)
- Hoehn & Yahr stage 1-3
- Stable dopaminergic medication for ≥4 weeks
- Able to participate in moderate exercise program
Exclusion Criteria
- Secondary parkinsonism
- Significant cardiovascular disease
- Orthopedic limitations preventing exercise
- Already engaged in structured exercise (>150 min/week)
- Cognitive impairment (MoCA <24)
Sample Size
- Total: 120 participants (60 exercise, 60 control)
- Power: 80% power to detect 20% difference in BDNF levels (α=0.05)
- Stratification: Equal BDNF Val66Met genotype distribution in both arms
Study Arms
Exercise Intervention Group (n=60)
- Type: Aerobic exercise (treadmill, cycling)
- Duration: 12 months
- Frequency: 3 sessions/week
- Intensity: 60-75% heart rate reserve
- Supervision: Bi-weekly in-person, home-based with weekly check-ins
Control Group (n=60)
- Intervention: Stretching and flexibility exercises (non-aerobic)
- Duration: 12 months
- Frequency: 2 sessions/week
- Intensity: Low intensity (RPE <10)
Outcome Measures
...Experiment Overview
Hypothesis being tested: Exercise-BDNF-Mitochondrial Resilience Hypothesis
Primary Objective: Determine whether physical exercise-induced BDNF elevation correlates with improved mitochondrial quality control markers and reduced neuroinflammation in Parkinson's Disease patients.
Study Design: Prospective cohort study with 12-month follow-up
Study Population
Inclusion Criteria
- Age 45-75 years
- Diagnosis of idiopathic Parkinson's Disease (UK Brain Bank criteria)
- Hoehn & Yahr stage 1-3
- Stable dopaminergic medication for ≥4 weeks
- Able to participate in moderate exercise program
Exclusion Criteria
- Secondary parkinsonism
- Significant cardiovascular disease
- Orthopedic limitations preventing exercise
- Already engaged in structured exercise (>150 min/week)
- Cognitive impairment (MoCA <24)
Sample Size
- Total: 120 participants (60 exercise, 60 control)
- Power: 80% power to detect 20% difference in BDNF levels (α=0.05)
- Stratification: Equal BDNF Val66Met genotype distribution in both arms
Study Arms
Exercise Intervention Group (n=60)
- Type: Aerobic exercise (treadmill, cycling)
- Duration: 12 months
- Frequency: 3 sessions/week
- Intensity: 60-75% heart rate reserve
- Supervision: Bi-weekly in-person, home-based with weekly check-ins
Control Group (n=60)
- Intervention: Stretching and flexibility exercises (non-aerobic)
- Duration: 12 months
- Frequency: 2 sessions/week
- Intensity: Low intensity (RPE <10)
Outcome Measures
Primary Outcomes
| Measure | Timepoints | Method |
|---------|------------|--------|
| Serum BDNF | Baseline, 3, 6, 12 months | ELISA |
| Serum Parkin | Baseline, 3, 6, 12 months | ELISA |
| Serum PINK1 | Baseline, 3, 6, 12 months | ELISA |
| UPDRS Part III (Motor) | Baseline, 3, 6, 12 months | Clinical exam |
Secondary Outcomes
| Measure | Timepoints | Method |
|---------|------------|--------|
| Neuroinflammation (IL-6, TNF-α) | Baseline, 6, 12 months | Multiplex ELISA |
| Mitochondrial DNA copy number | Baseline, 6, 12 months | qPCR |
| CSF BDNF (subset n=30) | Baseline, 12 months | ELISA |
| Autonomic function (SCOPA-AUT) | Baseline, 12 months | Questionnaire |
| Quality of life (PDQ-39) | Baseline, 6, 12 months | Questionnaire |
Exploratory Outcomes
- Gut [microbiome](/entities/microbiome) composition (16S rRNA sequencing)
- Peripheral inflammatory monocytes (flow cytometry)
- Exosomal [alpha-synuclein](/proteins/alpha-synuclein)
BDNF Genotyping
Genotype Stratification
All participants genotyped for BDNF Val66Met polymorphism (rs6265):
- Val/Val: Expected normal BDNF trafficking
- Val/Met: Reduced activity-dependent BDNF secretion
- Met/Met: Significantly impaired BDNF release
Hypothesized Effect Modification
The exercise-BDNF relationship may be attenuated in Met carriers due to impaired BDNF trafficking. This will be tested via interaction analysis.
Statistical Analysis Plan
Primary Analysis
- Mixed-effects linear regression (group × time interaction)
- Adjusted for: age, sex, disease duration, baseline UPDRS, medication dose
Secondary Analyses
- Correlation: ΔBDNF vs ΔUPDRS, ΔBDNF vs mitochondrial markers
- Genotype stratification: Compare effect sizes by Val66Met genotype
- Mediation analysis: Does change in inflammatory markers mediate BDNF-motor association?
Power Calculation
- n=60/group provides 80% power to detect:
- 25% increase in serum BDNF (Cohen's d=0.5)
- 15% reduction in UPDRS progression
Data Collection Schedule
Risk Assessment
Potential Risks
- Exercise-related musculoskeletal injury
- Fatigue during exercise sessions
- Blood draw discomfort
Mitigation Strategies
- Supervised exercise program with gradual progression
- Exclusion of participants with cardiovascular contraindication
- Standard phlebotomy protocols
Expected Benefits
- Improved motor function
- Enhanced quality of life
- Potential disease-modifying effects (mechanistic)
Budget Estimate
| Item | Cost |
|------|------|
| Personnel (2 research coordinators) | 20,000 |
| BDNF/Parkin/PINK1 ELISAs (720 assays) | 3,200 |
| Inflammatory marker panel (240 assays) | 4,400 |
| Genotyping (120 samples) | ,600 |
| Exercise equipment/supervision | 5,000 |
| Participant compensation | 6,000 |
| CSF collection (30 samples) | ,000 |
| Total | 51,200 |
Ethical Considerations
- IRB approval required
- Informed consent for genotyping
- Genetic counseling available for participants
- Data safety monitoring board for adverse events
Expected Timeline
- Month 0-2: IRB approval, recruitment start
- Month 2-14: Enrollment (12 months)
- Month 14-26: Follow-up completion
- Month 26-30: Data analysis and manuscript preparation
See Also
- [Experiment Index](/experiments/experiment-index)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
External Links
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
References
[Unknown, Physical activity and Parkinson disease risk (JAMA Neurol 2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/30668840/)
[Unknown, BDNF Val66Met polymorphism and exercise (Nat Rev Neurosci 2007) (2007)](https://pubmed.ncbi.nlm.nih.gov/17684528/)
[Unknown, Exercise increases serum BDNF in humans (J Appl Physiol 2018) (2018)](https://pubmed.ncbi.nlm.nih.gov/29327843/)
[Unknown, Mitophagy in Parkinson's disease (Nat Rev Neurol 2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/30610316/)
[Unknown, BDNF and dopaminergic neuron survival (Exp Neurol 2002) (2002)](https://pubmed.ncbi.nlm.nih.gov/12445574/)